研究者業績

松村 貴由

マツムラ タカヨシ  (Takayoshi Matsumura)

基本情報

所属
自治医科大学 分子病態治療研究センター 心血管・遺伝学研究部 教授

研究者番号
80436485
J-GLOBAL ID
202101014043069173
researchmap会員ID
R000016874

論文

 52
  • Takayoshi Matsumura, Eiji Ohtaki, Kazuhiko Misu, Tetsuya Tohbaru, Ryuta Asano, Masatoshi Nagayama, Koichi Kitahara, Jun Umemura, Tetsuya Sumiyoshi, Mitsuhiko Kawase, Takao Ida, Hitoshi Kasegawa, Saichi Hosoda
    International journal of cardiology 86(2-3) 217-23 2002年12月  
    BACKGROUND: Recent studies on the etiology of aortic valve disease in the US showed a decrease in rheumatic valve disease and an increase in age-related degenerative disease. The purpose of this study was to describe the etiology of aortic valve disease and its temporal changes in Japan, based on a large number of cases. METHODS: The medical charts of all patients who underwent aortic valve replacement at our institute between 1977 and 1999 were reviewed. Among the 600 patients analyzed, 213 (36%) had pure aortic stenosis, 265 (44%) had pure aortic regurgitation, and 122 (20%) had combined stenosis and regurgitation. RESULTS: The causes were rheumatic change (49%), degenerative change (19%), bicuspid valves (18%), infective endocarditis (5%) and others (9%). Rheumatic disease continued to be the most common cause of aortic stenosis, but its frequency decreased from 100% in 1977-1979 to 37% in 1995-1999. In contrast, the frequency of degenerative change among stenotic valves increased recently from 11% in 1990-1994 to 30% in 1995-1999. Similarly, rheumatic disease remained to be the leading cause of aortic regurgitation, with a decline in frequency from 46% in 1985-1989 to 27% in 1995-1999. The percentage of degenerative change among regurgitant valves did not change appreciably. CONCLUSIONS: There was a shift in the causes of aortic valve disease, with a decrease in rheumatic disease and an increase in degenerative disease. This trend was similar to that observed in the US. These findings suggest the increasing importance of aortic valve disease due to degenerative change.
  • Takayoshi Matsumura, Kensuke Tsushima, Eiji Ohtaki, Kazuhiko Misu, Tetsuya Tohbaru, Ryuta Asano, Masatoshi Nagayama, Koichi Kitahara, Jun Umemura, Tetsuya Sumiyoshi, Saichi Hosoda
    Journal of cardiology 39(5) 253-7 2002年5月  
    OBJECTIVES: Whether beta-blocker therapy changes the circulating levels of cytokines as congestive heart failure improves remains uncertain. METHODS: Nine patients with idiopathic dilated cardiomyopathy, who had previously received conventional treatment and were classified as New York Heart Association (NYHA) functional class II, received carvedilol by stepwise dose increase up to 20 mg daily, and the plasma interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were measured. RESULTS: IL-6 was significantly reduced from 0.80 +/- 0.49 pg/ml before therapy to 0.21 +/- 0.08 pg/ml after carvedilol was increased to 20 mg daily (p < 0.05). Moreover, IL-6 level had already decreased significantly compared to the baseline when the dose of carvedilol had reached 10 mg daily (0.28 +/- 0.12 pg/ml, p < 0.05). TNF-alpha levels did not change significantly. CONCLUSIONS: These results demonstrate that IL-6 concentration is significantly decreased by beta-blocker therapy. The efficacy for heart failure may be related to the change of IL-6 concentration.

MISC

 12
  • 大里 元美, Ong Kelly Ooi Kee, Mok Michelle Meng Huang, 横溝 智雅, 松村 貴由, 須田 年生, 麻生 範雄, Koeffler Phillip, Tenen Daniel G., 清水 律子, 山本 雅之, 伊藤 嘉明, Yeoh Allen Eng-Juh, Chng Wee Joo
    臨床血液 59(9) 1700-1700 2018年9月  
  • 藤原 志保, 大里 元美, 松村 貴由, 須田 年生, 渡邊 祐子, 下村 泰三, 鈴島 仁
    臨床血液 59(9) 1662-1662 2018年9月  
  • Ayako Nakamura-Ishizu, Takayoshi Matsumura, Terumasa Umemoto, A'Qilah Abdul Majeed, Toshio Suda
    EXPERIMENTAL HEMATOLOGY 44(9) S91-S91 2016年9月  
  • Chikashi Terao, Hajime Yoshifuji, Akinori Kimura, Takayoshi Matsumura, Koichiro Ohmura, Meiko Takahashi, Masakazu Shimizu, Takahisa Kawaguchi, Zhiyong Chen, Taeko K. Naruse, Aiko Sato-Otsubo, Yusuke Ebana, Yasuhiro Maejima, Hideyuki Kinoshita, Kosaku Murakami, Daisuke Kawabata, Yoko Wada, Ichiei Narita, Junichi Tazaki, Yasushi Kawaguchi, Hisashi Yamanaka, Kimiko Yurugi, Yasuo Miura, Taira Maekawa, Seishi Ogawa, Issei Komuro, Ryozo Nagai, Ryo Yamada, Yasuharu Tabara, Mitsuaki Isobe, Tsuneyo Mimori, Fumihiko Matsuda
    American Journal of Human Genetics 93(2) 289-297 2013年8月8日  
    Takayasu arteritis (TAK) is an autoimmune systemic vasculitis of unknown etiology. Although previous studies have revealed that HLA-B*52:01 has an effect on TAK susceptibility, no other genetic determinants have been established so far. Here, we performed genome scanning of 167 TAK cases and 663 healthy controls via Illumina Infinium Human Exome BeadChip arrays, followed by a replication study consisting of 212 TAK cases and 1,322 controls. As a result, we found that the IL12B region on chromosome 5 (rs6871626, overall p = 1.7 × 10-13, OR = 1.75, 95% CI 1.42-2.16) and the MLX region on chromosome 17 (rs665268, overall p = 5.2 × 10-7, OR = 1.50, 95% CI 1.28-1.76) as well as the HLA-B region (rs9263739, a proxy of HLA-B*52:01, overall p = 2.8 × 10-21, OR = 2.44, 95% CI 2.03-2.93) exhibited significant associations. A significant synergistic effect of rs6871626 and rs9263739 was found with a relative excess risk of 3.45, attributable proportion of 0.58, and synergy index of 3.24 (p ≤ 0.00028) in addition to a suggestive synergistic effect between rs665268 and rs926379 (p ≤ 0.027). We also found that rs6871626 showed a significant association with clinical manifestations of TAK, including increased risk and severity of aortic regurgitation, a representative severe complication of TAK. Detection of these susceptibility loci will provide new insights to the basic mechanisms of TAK pathogenesis. Our findings indicate that IL12B plays a fundamental role on the pathophysiology of TAK in combination with HLA-B*52:01 and that common autoimmune mechanisms underlie the pathology of TAK and other autoimmune disorders such as psoriasis and inflammatory bowel diseases in which IL12B is involved as a genetic predisposing factor. © 2013 The American Society of Human Genetics.
  • Junichi Ishida, Toru Suzuki, Kenichi Aizawa, Daigo Sawaki, Takayoshi Matsumura, Scott L. Friedman, Ryozo Nagai
    CIRCULATION 126(21) 2012年11月  

共同研究・競争的資金等の研究課題

 4